Executive Employment Agreement effective as of February 14, 2022, by and between Kiromic BioPharma, Inc. and Daniel Clark
Exhibit 10.3
EXECUTIVE EMPLOYMENT AGREEMENT
THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), is effective as of February 14, 2022 (the “Effective Date”) by and between Kiromic Biopharma, Inc., a Delaware corporation (the “Company”), and Dan Clark (the “Executive”). Throughout the remainder of the Agreement, the Company and Executive may be individually referred to as a ‘party” or collectively referred to as “the parties.”
W I T N E S S E T H:
WHEREAS, the Company wishes to continue to employ the Executive, and the Executive desires to accept such continued employment with the Company, upon the terms and conditions of this Agreement;
NOW, THEREFORE, in consideration of the foregoing, of the mutual promises herein, and of other good and valuable consideration, including the continued employment of the Executive by the Company and the compensation to be received by the Executive from the Company from time to time, and specifically the compensation to be received by the Executive pursuant to Section 4 below, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending legally to be bound, hereby agree as follows:
| |
2
3
4
5
6
7
If to the Company,
Kiromic Biopharma, Inc.
7707 Fannin Street, Suite 140
Houston, TX 77054
Attn: CEO
If to Executive:
Dan Clark
837 West 24th St.
Houston, TX 77008
8
9
[The remainder of this page is intentionally left blank.]
10
IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above written.
By: /s/ Daniel Clark Daniel Clark | KIROMIC BIOPHARMA INC. By:/s/ Pietro Bersani Name: Pietro Bersani Title: Interim Chief Executive Officer |
[Signature page for Executive Employment Agreement.]
11